July Grants — October 2008

Federal Grants

Abrams, J., NIH, Molecular and Genetic of Programmed Cell Death, $225,000; Bezprozvanny, I., NIH, 2008 Calcium Signaling and Disease SGP Conference, $318,678; Bibb, J., NIH/ Cincinnati Children’s Hosp. Med, Ctr., Genetic and Molecular Signaling in Heart Failure, $15,187; Burma, S., NASA, Molecular and Cellular Effects of Heavy Ion Fragmentation Due to Shielding, $224,237; Cameron, J., NIH, Regulation of Programmed Cell Death in C elegans, $161,191.

Chan, R., NIH, Biomechanical Characterization of Vocal Fold Tissues, $275,492; Chen, D., NASA, Mechanisms of the Repair of HZE-Induced DNA Double-Strand Breaks in Human Cells, $196,001; Chook, Y., NIH, Structures and Mechanisms of Nuclear Import and Export, $167,260; Chuang, D., NIH, Structure and Function of Mitochondrial Protein Kinases, $151,361; Cohen, J., NIH, Genetic Susceptibility to Adverse Metabolic Consequences of Obesity, $475,000.

 

Crandall, C., NIH, Neural and Non-Neural Modulators of Skin Blood Flow and Sweating in Humans, $302,705; DeHaven, M., NIH, The GOODNEWS (Genes, Nutrition, Exercise, Wellness, and Spiritual Growth) Trial, $361,275; Dietschy, J., NIH, UT Gastroenterology/Hepatology Research Training Program, $25,972; Eisch, A., NIH, New Horizons in Adult Neurogenesis, $85,446.

Elmquist, J., NIH, CNS Pathways Regulating Ghrelin Effects on Body Weight, $185,843; Elmquist, J., NIH/Beth Israel Deaconess Med. Ctr., Peripheral and Central Interactions in Energy Balance: Project 1, $73,192; Falck, J., NIH/Med. Coll. of Wisc., Cytochrome P450 Eicosanoids and Myocardial Injury, $15,018; Falck, J., NIH/Univ. of Cincinnati, P450 Eicosanoids Reduce Inflammation and Promote Recovery After Brain Injury, $21,875; Fontoura, B., NIH, Regulation of mRNA Export By Viral Proteins, $190,000.

Fowler, M., NIH, TRPC Channels in Dopamine Regulation of Prefrontal Cortical Excitability, $27,420; Gao, J., NIH, Ultrasensitive MR Probes for Molecular Diagnosis of Lung Cancer, $207,500; Garcia, C., NIH, The Molecular Basis of Familial Spontaneous Pneumothorax, $140,000; Garcia-Martinez, J.V., NIH, Infectious Diseases Training Program, $109,644; Gardner, K., NIH, Structural Studies of PAS Domain Signaling Mechanisms, $193,670.

Hammes, S., NIH, Nongenomic Steroid Signaling in Oocytes, $210,994; Hamra, F., NIH, Gene Targeting in Rat Spermatogonial Stem Cells, $147,000; Horton, J., NIH, Taskforce for Obesity Research at Southwestern, $245,250; Horton, J., DHHS, Health Care and Other Facilities, $189,677; Huber, K., NIH, Mechanisms of mGluR-Dependent Synaptic Plasticity, $200,000.

Hutchison, M.R., NIH, Examination of the Prepubertal Mammalian Growth Plate, $114,515; Igarashi, P., NIH, Renal Control of Body Composition and Blood Pressure, $267,516; Jacobe, H., NIH, Assessment in Morphea for the Establishment of Non-Cutaneous Disease, $100,000; Johnson, R., NIH, Limitation to Exercise After Pneumonectomy, $255,535; Kuro-o, M., NIH, Proteomics of Mouse Models for Aging and Longevity, $185,843.

Lehrman, M., NIH, N-Glycosylation and ER Stress, $245,000; Lingvay, I., NIH, Role of Pancreatic Triglycerides in Beta-Cell Dysfunction, $140,000; Liu, Q., NIH, Molecular Mechanism of Small RNA- Induced RNA Silencing, $184,490; Livingston, E., NIH, Human Biology Core, Project 10 of 10, $265,533; Livingston, E., NIH, Human Biology Core, Project 10 of 10, $50,000 (supplement).

Lotan, Y., NIH/UT M.D. Anderson Cancer Center, Phase I and II Clinical Trials of Chemopreventive Agents: Phase II Placebo-Controlled Trial of Preoperative Lycopense Supplementation in Prostate Cancer Patients, $21,975; Lotan, Y., NIH/UT M.D. Anderson Cancer Center, Phase I and II Clinical Trials of Chemopreventive Agents: Phase II Placebo-Controlled Trial of Preoperative Lycopense Supplementation in Prostate Cancer Patients, $22.875; Lu, H., NIH/UT Dallas, Neuroimaging of Dedifferentiation and Memory Across the Lifespan, $7,679; Malloy, C., NIH, Skeletal Mitochondrial Function, Body Weight, and Diabetes, Project 5 of 10, $245,250; Malloy, C., NIH/Med. Coll. of Ga., Coordinating and Bioinformatics Unit for the AMDCC/ MMPC, $338,261.

Mangelsdorf, D., NIH, Mechanisms of Drug Action and Disposition, $336,382; Mason, R., DOD, Breast-Tumor Detection and Treatment Using Tarvacin Labeled With Arsenic Radionuclides, $100,000; Mendelson, C., NIH, Initiation of Human Labor: Prevention of Prematurity, $931,805; Michaely, P., NIH, Characterization of the Role of ARH on LDLR Function, $145,650; Nelson, O., NIH, Familial Alzheimer’s Disease-Linked Presenilin Mutants and Calcium Leak, $27,072.

Niederkorn, J., NIH, Transplant and Tumor Rejection Processes Within the Eye, $245,000; Nirodi, C., NIH, Role of EGFR in DNA Repair and Radiation Response in Non Small Cell Lung Cancer, $166,000; Parker, K., NIH, Endocrine and Metabolism Training Grant, $268,378; O’Suilleabhain, P., NIH/Mass. General Hosp., Coenzyme Q10 in Huntington’s Disease, $5,414; Parker, K., NIH, Steroidogenic Factor 1: Mediator of Gonadal Function, $188,167; Parks, E., NIH, Effect of Dietary Macronutrient Composition and Weight Loss on Liver Substrate Me, $284,774.

Repa, J., NIH, TORS: Interdisciplinary Research Training Program, Project 8 of 10 RL9, $114,278; Repa, J., NIH, TORS; Interdisciplinary Research Training Program, Project 8 of 10 TL1, $101,724; Richards, B., NIH/UTHSC Houston, Genetic Studies of Clubfoot, $16,124; Rogers, Z., NIH, Pediatric Hydroxyurea Phase III Clinical Trial: BABY HUG, $54,410; Rothermel, B., NIH, Modulating Calcineurin Signaling Pathways in Muscle, $250,000.

Rush, A.J., NIH/Univ. of Mich., Learning Adaptive Treatment Strategies in Mental Health, $17,975; Russell, D., NIH, Mouse Phenotype Core, Project 9 of 10, $236,680; Schaffer, J., NIH, NICHD Pelvic Floor Disorders Network, $145,696; Scherer, P., NIH, Establishment of Adiponectin as a PPARgamma Cofactor, $49,646 (Davis, K., fellow); Shakil, A., DHHS, Residency Training in Primary Care, $181,376.

Shaul, P., NIH, Oxysterols, Estrogen, Receptors Antagonism and Vascular Disease, $242,750; Shay, J., NIH, Cancer Biology Training Grant, $258,424; Sherry, A.D., NIH, Metabolism in the Heart By NMR, $250,000; Smith, D., NIH, Genetic Analysis of Olfaction, $59,524; Souza, R., NIH, Role of Acid in the Development of Barrett’s Esophagus, $25,000.

Souza, R., NIH, Role of Acid in the Development of Barrett’s Esophagus, $171,500; Souza, R., NIH, Role of Acid in the Development of Barrett’s Esophagus, $25,000 (supplement); Soyombo-Shoola, A., NIH, Molecular and Functional Characterization of Mucolipin-1, $27,778; Tansey, M., NIH, TNF Signaling in Neurodegeneration, $218,475; Turcotte, M., NIH, G Protein Networks: Modeling, Simulation and Analysis, $144,295.

van Oers, N., PTPNA Functions in Lymphocytes, $150,000; Vitetta, E., NIH, Development of a Lyophilized Intradermal/Intranasal Ricin Vaccine, $392,163; Wakeland, E., NIH, Genetic Dissection of SLE Pathogenesis, $975,280; White, M., NIH, The RaLGTPase Regulatory Network, $152,000; White, P., NIH, Functions of Very Large G-Protein Coupled Receptor-1, $214,113.

Wooding, S., NIH, Evolutionary Dissection of Complex Traits, $98,605; Wu, L., NIH, Image Based Phenotypic Profiling of Single-Cell Responses to Perturbations, $254,586; Yarovinsky, F., NIH, Molecular Pathways Involved in TLR11-Mediated IL-12 Production by Dendritic Cells, $200,000; Zigman, J., NIH, Ghrelin and Reward, $200,000; Zinn, A., NIH/Thomas Jefferson Univ., Androgen Effect on Motor/Cognitive Outcome in Klinefelter Syndrome, $17,796.

Nonfederal Grants

Cobb, M., Amer. Diabetes Assn., MAP Kinases in Beta-Cell Function Mentor-Based Postdoctoral Fellowship, $45,000; Drazner, M., Medtronic, CRDM Education Services, Medtronic Postdoctoral Fellowship Support, $30,000; Garcia-Martinez, J.V., amfAR Aids Research, In Vivo Modeling of HIV Persistence and its Eradication, $56,818 (Denton, P., fellow); Gazdar, A., IASLC, Univ. of Colo. Cancer Ctr., Induction c-MET Signaling Pathway Through HIF-1 a and COX-2 in Non-Small-Cell Lung Cancer Cell Lines, $40,000.

Goldstein, J., Ara Parseghian Med. Research Fndtn., Biochemical Characterization of NPC1 and NPC2 Proteins, $75,000 (Infante, R., fellow); Hill, J., Amer. Diabetes Association, Forkhead Transcription Factors Modulate Insulin Signaling and Contribute to the Pathogenesis of Diabetic Cardiomyopathy, $45,000 (Battiprolu, P., fellow); Hsieh, J., Flight Attendant Medical Research Institute, Small-Peptide Therapy on Metastatic Prostate Cancer, $100,000; Johnson, J., Malia’s CORD Fndtn., Spinal Cord Progenitor Cells: Distinct Molecular Characteristics and Involvement in Tumor Formation, $100,000.

Le, L., Burroughs Wellcome Fund, Cell of Origin and Tumor Microenvironment in NF1-Associated Neurofibroma Development, $140,000; Lee, K., Amer. Academy of Otolaryngology Head and Neck Surgery, Eph-Ephrin Signaling in Cochlear Innervation, $36,364; Liu, S., Human Frontier Science Program, Probing the Mechanism of the Cleavage Reaction in Catalytic RNAs, $90,909; Liu, S., Amer. Liver Fndtn., Post-Translation Regulation of Sinusoidal Endothelial Cell eNOS by the GPCR Interacting Protein, GIT1, $75,000.

Parada, L., Amer. Brain Tumor Assn., Analysis of the Functional Influence of microRNAs in Malignant Astrocytoma, $40,000 (Chen Y., fellow); Repa, J., Ara Parseghian Medical Research Fndtn., Nuclear Receptors as Targets for the Treatment of NPC Disease: Inflammation and Cholesterol Balance, $101,250; Roland, P., Med-El Corp., Health-Related Quality of Life in Young Cochlear Implant Users, $7,727 (Loy, B., fellow); Rosen, M., Cancer Research Inst., The Role of Lysine Methylation in Regulating the Actin Cytoskeleton, $40,000 (Da, J., fellow).

Saha, D., Flight Attendant Medical Research Inst., Modulation of Stereotactic Body Radiation Therapy to Improve Therapeutic Ratio, $100,000; Scaglioni, P., Concern Fndtn., Exploiting Oncogene Addiction in Lung Cancer Therapy, $50,000; Scherer, P., Amer. Diabetes Association, Inducible Activation of the XBP-1 Unfolded Protein Response Pathway, $45,000 (Deng, Y., fellow); Taurog, J., Arthritis Fndtn., Targeted Gene Deletion in Rats: Application to a Rat Model of Arthritis, $87,963.

Wai, C., Amer. Col. of Obstetricians and Gynecologists, Accelerating Wound Healing After Anal Sphincter Injury: Satellite Cell Recruitment, $30,000 (White, A., fellow); Wright, W., Amer. Federation for Aging Research, To Define the Mechanism of Telomere Extension by Telomerase in Human Cells, $40,000 (Zhao, Y., fellow); Yarovinsky, F., ACS, A Novel Transgenic Mouse Model for Chronic Inflammation: Linking Toll-Like Receptor Responses With Carcinogenesis, $40,000.

Pharmaceutical studies, dollar amounts not available

Collins, R., A Phase II, Multicenter, Open-Label Trial Evaluating the Activity and Tolerability of Study Drug in Progressive or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy; Diaz-Arrastia, R., A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Efficacy and Safety of 18 Months of Treatment With Study Drug in Participants With Mild to Moderate Alzheimer’s Disease; Dowell, J., A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Study Drug in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small-Cell Lung Cancer.

Iannaccone, S., A Phase 2b Efficacy and Safety Study of Study Drug in Subjects With Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy; Kenkel, J., Protocol for the Post-Approval Study of Study Device for Correction of Nasolabial Folds; McGuire, D., A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of Study Drug Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease.

Parmar, S., Protocol Post-Text Supplement: 1, A Prospective, Non-Interventional, Multicenter Registry in Iron- Overloaded Lower-Risk Myelodysplastic Patients; Rosenberg, R., A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Study Drug in Alzheimer’s Disease; Rosenberg, R., A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Study Drug in Patients With Mild to Moderate Alzheimer’s Disease Who Are Apolipoprotein Eε4 Carriers; Sanchez, P., A Phase 1, Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Study Drug in Children (2-5 Years and 6-11 Years) and Adolescents (12-16 Years) With Esophageal Candidiasis or Other Invasive Candidiasis.

Share: